Patient explainer · Learn
Autologous vs. donor-derived stem cells.
Your own cells, harvested and used in the same procedure, or cells from a different person, often manufactured at scale. The FDA treats these very differently and so do we.
Direct answer
Autologous = your own cells, harvested and used in the same procedure. Donor-derived (allogeneic) = cells from a different person, often umbilical cord blood, placental tissue, or amniotic membrane, typically manufactured at scale and shipped to clinics.
01 · Definitions
The vocabulary, plainly.
Your own cells. Harvested from your body, bone marrow from your iliac crest, fat from your flank, or blood from your vein, and used in your own procedure. No donor. No other person's biology.
Donor-derived cells. From a different person. Almost always processed and manufactured at scale before being shipped to clinics.
Specifically, cells from birth-associated tissues: umbilical cord blood, umbilical cord tissue (Wharton's jelly), placental tissue, amniotic membrane, amniotic fluid. These are collected after delivery, processed by manufacturers, and sold to clinics for injection. They are donor-derived and almost always require FDA approval to market for any specific indication.
A regulatory term, cells that have been only lightly processed (centrifugation, filtration, separation) without altering their relevant biological characteristics. Autologous bone marrow concentrate (BMAC) prepared in a same-day procedure typically qualifies.
Cells grown in culture in a lab to increase their number, often over days to weeks. Once cells are expanded, they typically lose their "minimally manipulated" status and cross into FDA drug-product territory: requiring approval before they can be marketed.
02 · The regulatory line
How the FDA treats each.
The framework is the Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P) framework, codified at 21 CFR 1271.1 It draws a hard line between two categories:
Cells that meet specific criteria: minimally manipulated, used homologously, not combined with another article, with no systemic effect or dependence on metabolic activity. These can be marketed without FDA pre-market approval. Same-day, autologous, minimally-manipulated bone marrow concentrate typically falls into this category.
Cells that don't meet those criteria. Expanded cells, non-homologous use, combination products, products that depend on metabolic activity for their primary effect. These are regulated as drugs or biologics, and require an Investigational New Drug (IND) application or full FDA approval before marketing. Most donor-derived perinatal products fall into this category.
The practical effect: an autologous bone-marrow procedure performed in a single visit, with no expansion and no donor cells, can operate as a clinical procedure. A donor-derived umbilical-cord or placental product injected for the same indication usually requires full FDA approval: which most marketed products do not have.
Plain-language summary
Same-day, your-own cells = clinical procedure. Donor cells, especially from cord/placenta/amnion = drug product that needs FDA approval.
03 · Where enforcement is focused
Why the FDA has gone after donor-derived clinics.
Regulatory framing, Boulder Biologics
"The FDA has raised particular concern regarding allogeneic (donor-derived) stem cell products, including umbilical cord, placental, and amniotic products, marketed outside of approved clinical trials. This distinction is important, as FDA enforcement actions have primarily targeted unapproved donor-derived products marketed without appropriate authorization."
The pattern of FDA enforcement actions since the agency began ramping up oversight in 2017 has been consistent. Almost all major actions, warning letters, permanent injunctions, criminal referrals, have targeted clinics or manufacturers handling donor-derived products.2,3
The reasons the FDA gives are clinical, not philosophical:
- Patient harm from contamination. Donor products manufactured at scale, especially with inadequate sterility controls, have caused bacterial sepsis, including bloodstream infections requiring hospitalization. The agency has documented multiple outbreaks tied to specific manufacturers.4
- Patient harm from unproven claims. Donor-product clinics frequently market for indications (ALS, autism, MS, severe arthritis, COPD, diabetes) where no evidence supports the claimed benefit and where patients may forgo evidence-based care.
- Lack of identity, potency, or sterility documentation. Donor products vary widely from batch to batch, with poor quality control. Many products marketed as containing "millions of live stem cells" have been shown on testing to contain few or no live cells.
- Marketing language that misleads patients. "FDA registered," "regenerative," "cure," "reverse aging", all language the agency has cited as misleading in enforcement letters.
04 · The marketing reality
Why patients encounter donor products anyway.
Despite the regulatory exposure and the FDA enforcement record, donor-derived "stem cell" products remain widely marketed in the U.S. Several reasons:
- Convenience for clinics. Donor products ship from manufacturers ready-to-inject. No harvesting equipment, no on-site lab, no aspiration procedure. A clinic can offer "stem cell therapy" with minimal capital investment and no specialized procedural training.
- The word "stem cell" sells. Patients searching for help with chronic conditions find clinics offering "stem cells" and reasonably assume the regulatory and clinical equivalence is similar across providers. It isn't.
- Enforcement resource limits. The FDA has acknowledged that with thousands of clinics marketing unapproved products, formal enforcement has been slower than it would prefer. Many clinics operate for years before any action.2
- Implicit FDA-approval framing. Clinics often describe themselves as "FDA registered" (a near-meaningless distinction for an HCT/P establishment) or list their facility registration as if it were an approval. Patients reasonably read this as endorsement.
05 · How to evaluate a clinic
What to look for, and what to look out for.
Good signals:
- The clinic tells you the product or procedure is not FDA-approved, rather than implying it is.
- Cells used are autologous, your own, and the harvesting procedure is performed in the same visit.
- The clinic does not use donor-derived umbilical cord, placental, or amniotic products.
- The physician performs the procedure personally; it is not delegated to a midlevel provider.
- There is a clear regulatory-disclosure page that explains the HCT/P framework and the clinic's position within it.
- Outcome language is conservative: "may help," "supports," "evidence is preliminary", not "cures," "reverses," "regenerates."
- Informed-consent documentation discusses the investigational nature of the approach where applicable.
Red flags:
- "FDA approved" without naming a specific approved product and indication.
- "FDA registered" presented as if it means "approved."
- Donor-derived products (cord, placental, amniotic) advertised for orthopedic, neurological, autoimmune, or wellness indications.
- Cure language or specific outcome guarantees.
- Heavy use of before-and-after marketing.
- Claims of "millions of live stem cells" without supporting documentation of cell count and viability.
- Generalist marketing for everything, joints, brain, lungs, autoimmune, anti-aging.
06 · Where we stand
The Boulder Biologics position.
Boulder Biologics
"At Boulder Biologics, we use autologous stem cells only."
This is not a marketing position. It's a clinical and regulatory one. Specifically:
- No donor cells. No umbilical cord blood. No umbilical cord tissue. No placental products. No amniotic membrane. No amniotic fluid. No commercially-purchased cell products of any kind.
- No culture expansion. Your bone marrow aspirate is processed on-site within the same procedural window, returned to your own body the same day, and the cellular composition is what your marrow naturally contains, not what a lab grew.
- No genetic modification. No engineered cells. No CAR-derivatives. No off-the-shelf cell lines.
- Patient-derived only. Every component of every procedure, bone marrow, adipose tissue when indicated, platelet-rich plasma, comes from your body, on the day of your procedure.
The autologous-only position is also the position that allows us to operate within the same-surgical-procedure exception of 21 CFR 1271.15(b), as a clinical procedure performed within the framework the FDA's HCT/P regulations establish.
07 · Common questions
Frequently asked.
Are donor-derived stem cells ever appropriate? +
Yes, in the right context. Hematopoietic stem cell transplants (HSCT) for blood cancers and certain inherited disorders are donor-derived (or in some cases autologous) and have full FDA approval. These are not the same as the donor-derived "stem cell injection" marketed for joint pain, autism, or anti-aging.
The key distinction is: an FDA-approved allogeneic product, used for an approved indication, in an approved setting, is appropriate. A commercially-sold allogeneic product, used off-label, by a clinic with no IND filing, is not.
If donor-derived products were better, wouldn't more clinics use them? +
The popularity of donor-derived products in the U.S. "stem cell clinic" market is driven by convenience and economics, not by clinical superiority. Donor products are easy to stock and inject; autologous procedures require on-site lab capacity, bone-marrow aspiration training, and same-day processing infrastructure. The economics favor donor products for clinics that aren't equipped for autologous work, even though the regulatory and clinical position is harder to defend.
What about MSC immunogenicity, aren't allogeneic MSCs "immune-privileged"? +
That was the original framing, but the literature has moved. Recent work shows that allogeneic MSCs can provoke a measurable immune response in the host, particularly after repeat dosing or once they begin to differentiate (which up-regulates MHC class I and II expression).5,6 The "immune-privileged" claim is now widely considered outdated.
For a deeper read, see our science explainer on mesenchymal stromal cells, specifically the section on allogeneic immunogenicity.
How do I know if a clinic is using autologous or donor cells? +
Ask directly: "Are you using my own cells, harvested today, or are you using a product that arrives in a vial from a supplier?" A clinic using autologous material will be able to describe the harvesting procedure (typically iliac crest bone marrow aspiration); a clinic using donor products often defers to the manufacturer for source details. If the answer involves anything labeled "umbilical cord," "Wharton's jelly," "placental," "amniotic," or a brand name like StemFx, Liveyon, RegenMD, etc.: those are donor products.
References
Sources cited.
- 21 CFR Part 1271, Human Cells, Tissues, and Cellular and Tissue-Based Products. Electronic Code of Federal Regulations.
- U.S. Food and Drug Administration. Statement on FDA's continued efforts to stop stem cell clinics and manufacturers from marketing unapproved products that put patients at risk. Press release, June 2019.
- U.S. Food and Drug Administration. Statement on stem cell clinic permanent injunction and FDA's ongoing efforts to protect patients from risks of unapproved products. Press release, June 2019.
- Centers for Disease Control and Prevention. Notes from the Field: Septic Arthritis Caused by Granulicatella adiacens and Pseudomonas aeruginosa Following Umbilical Cord Blood–Derived Product Injection. MMWR. 2018.
- Ankrum JA, Ong JF, Karp JM. MSCs: immune evasive, not immune privileged. Nat Biotechnol. 2014;32(3):252–60.
- Joswig AJ, Mitchell A, Cummings KJ, et al. Repeated intra-articular allogeneic MSC injection causes adverse response vs autologous in equine model. Stem Cell Res Ther. 2017;8(1):42.
Related patient explainers